Expert forum
Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip.
2017-12-08 08:11來源:原版作者:Sheng W
Circulating tumor cells (CTCs) from peripheral blood hold important information for cancer diagnosis and disease monitoring. Analysis of this "liquid biopsy" holds the promise to usher in a new era of personalized therapeutic treatments and real-time monitoring for cancer patients. But the extreme rarity of CTCs in blood makes their isolation and characterization technologically challenging. This paper reports the development of a geometrically enhanced mixing (GEM) chip for high-efficiency and high-purity tumor cell capture. We also successfully demonstrated the release and culture of the captured tumor cells, as well as the isolation of CTCs from cancer patients. The high-performance microchip is based on geometrically optimized micromixer structures, which enhance the transverse flow and flow folding, maximizing the interaction between CTCs and antibody-coated surfaces. With the optimized channel geometry and flow rate, the capture efficiency reached >90% with a purity of >84% when capturing spiked tumor cells in buffer. The system was further validated by isolating a wide range of spiked tumor cells (50-50,000) in 1 mL of lysed blood and whole blood. With the combination of trypsinization and high flow rate washing, captured tumor cells were efficiently released. The released cells were viable and able to proliferate, and showed no difference compared with intact cells that were not subjected to the capture and release process. Furthermore, we applied the device for detecting CTCs from metastatic pancreatic cancer patients' blood; and CTCs were found from 17 out of 18 samples (>94%). We also tested the potential utility of the device in monitoring the response to anti-cancer drug treatment in pancreatic cancer patients, and the CTC numbers correlated with the clinical computed tomograms (CT scans) of tumors. The presented technology shows great promise for accurate CTC enumeration, biological studies of CTCs and cancer metastasis, as well as for cancer diagnosis and treatment monitoring.
(Lab Chip. 2014 Jan 7;14(1):89-98.)
版權(quán)聲明:
本網(wǎng)站所有注明“來源:“陽普醫(yī)療”的文字、圖片和音視頻資料,版權(quán)均屬于陽普醫(yī)療所有,非經(jīng)授權(quán),任何媒體、網(wǎng)站或個人不得轉(zhuǎn)載,授權(quán)轉(zhuǎn)載時須注明
“來源:陽普醫(yī)療”。本網(wǎng)所有轉(zhuǎn)載文章系出于傳遞更多信息之目的,且明確注明來源和作者,不希望被轉(zhuǎn)載的媒體或個人可與我們聯(lián)系,我們將立即進(jìn)行刪除處理。
網(wǎng)友評論:
版主信息
昵稱:Mandy Luo
郵箱:mandyluo@improve-medical.com
相關(guān)閱讀
- > 《醫(yī)學(xué)拾萃》2023年12月刊:簡述實(shí)驗(yàn)室信息管理系統(tǒng)發(fā)展歷程
- > 《醫(yī)學(xué)拾萃》2023年10月刊:分析前標(biāo)本處理對神經(jīng)元特異性烯醇化酶(NSE)檢測的影響
- > 《醫(yī)學(xué)拾萃》2023年8月刊:PSA 檢測的標(biāo)本處理、質(zhì)量控制及其臨床應(yīng)用
- > 《醫(yī)學(xué)拾萃》2023年6月刊:真空采血管標(biāo)本放置時間和溫度對常見檢驗(yàn)項目的影響
- > 《醫(yī)學(xué)拾萃》2023年4月刊:游離 DNA 管使用現(xiàn)狀與展望
- > 《醫(yī)學(xué)拾萃》2023年2月刊:肝素管的臨床適用檢測項目與不適用項
- > 《醫(yī)學(xué)拾萃》2022年12月刊:血清分離技術(shù)及其對臨床生化檢驗(yàn)結(jié)果的影響
- > 《醫(yī)學(xué)拾萃》2022年10月刊:標(biāo)本處理對心肌肌鈣蛋白測定的影響
- > 《醫(yī)學(xué)拾萃》2022年8月刊:一種新型材料-水凝膠的合成及其應(yīng)用
- > 《醫(yī)學(xué)拾萃》2022年6月刊:RFID 技術(shù)及其在醫(yī)療和標(biāo)本管理中的應(yīng)用與發(fā)展